FDA Approves Qiagen's Therascreen EGFR as CDx for Boehringer Ingelheim's NSCLC Drug | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved for marketing Qiagen's therascreen EGFR test as a companion diagnostic test for Boehringer Ingelheim's new targeted treatment for metastatic non-small cell lung cancer, Qiagen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.